The translocation t(4;14) can be present only in minor subclones in multiple myeloma.
Fiche publication
Date publication
septembre 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis
Tous les auteurs :
Hebraud B, Caillot D, Corre J, Marit G, Hulin C, Leleu X, Lode L, Wetterwald M, Dib M, Rodon P, Voillat L, Royer B, Voog E, Fitoussi O, Stoppa AM, Garderet L, Kolb B, Maigre M, Boullanger N, Allangba O, Karlin L, Daguindau N, Legros L, Sohn C, Joubert MV, Lenain P, Facon T, Attal M, Moreau P, Avet-Loiseau H
Lien Pubmed
Résumé
PURPOSE: Although the translocation t(4;14) is supposed to be a primary event in multiple myeloma, we have been surprised to observe that in large relapse series of patients, the t(4;14) can be observed only in subpopulations of plasma cells, in contrast to what is seen at diagnosis. This observation raised the question of possible subclones harboring the translocation that would be observable only at the time of relapse. EXPERIMENTAL DESIGN: To address this issue, we analyzed by FISH a cohort of 306 patients for whom we had at least two samples obtained at different disease phases. RESULTS: We observed a "gain" of the t(4;14) in 14 patients, and conversely, a "loss" of the translocation in 11 patients. Two hypotheses were raised: either an acquisition of the translocation during evolution or the existence of small t(4;14)-positive subclones at the time of diagnosis. To address this question, we had the opportunity to analyze two patients at the time of diagnosis by RT-PCR (reverse transcription-polymerase chain reaction) to look for the chimeric Emu-MMSET transcript, and one patient positive at diagnosis, but negative at relapse. The samples were positive, supporting the second hypothesis. Furthermore, the IGH sequences of two patients who "lose" the t(4;14) were identical at diagnosis and relapse, confirming the existence of a common ancestral clone. CONCLUSION: Thus, the conclusion of this study is that the t(4;14) is not a primary event in multiple myeloma and that it can be present in silent subclones at diagnosis, but also at relapse.
Référence
Clin Cancer Res. 2013 Sep 1;19(17):4634-7